Failure of low‐dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment‐refractory rheumatoid arthritis
Keith S. Kanik(Pfizer (United States)), Ronald L. Wilder(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Yaakov Naparstek(Hebrew University of Jerusalem), Cheryl Yarboro(National Institutes of Health), Paul H. Plötz(National Institutes of Health)
Cited by 26
Related Papers
Therapy of Lupus Nephritis
|New England Journal of Medicine|1986|1.2k
A New Approach to the Classification of Idiopathic Inflammatory Myopathy
|Medicine|1991|974
Defective Reticuloendothelial System Fc-Receptor Function in Systemic Lupus Erythematosus
|New England Journal of Medicine|1979|531
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy
|The Journal of Experimental Medicine|2005|395